Voyager Acquisition Corp (NASDAQ: VACH) is a special purpose acquisition company (SPAC) formed to identify and complete a merger or acquisition with a private operating business. The company generates no operating revenue. Its capital structure centers on funds held in a trust account, with public shareholders entitled to approximately $10.05 per share upon redemption if a business combination is not completed. As of the 10-K filed March 10, 2026, VACH had entered into a Business Combination Agreement (BCA) with Veraxa Biotech Holding AG (PubCo) and related merger subsidiaries, under which VACH would merge into a subsidiary of PubCo, followed by Veraxa merging into PubCo. The Business Combination was expected to close in the first quarter of 2026, subject to shareholder approval and customary closing conditions. VACH completed its IPO in August 2024, with the underwriters fully exercising their over-allotment option on August 12, 2024. The sponsor, Voyager Acquisition Sponsor Holdco LLC, held 4,690,000 founder shares (Class B ordinary shares) as of the filing date, representing approximately 14.8% of total voting power.

Revenue model

VACH generates no operating revenue. As a SPAC, it funds operations through proceeds held in a trust account from its August 2024 IPO. The economic model is structured around completing a single qualifying business combination, after which the SPAC structure dissolves.

Products and services

VACH offers no commercial products or services. Its sole activity is sourcing, evaluating, and executing a business combination with a target company. The announced target as of the March 10, 2026 filing is Veraxa Biotech Holding AG, a biotech entity, via a two-step merger structure involving an initial merger and an acquisition merger.

Customers and end markets

VACH has no customers in the commercial sense. Its stakeholders are public shareholders holding Class A ordinary shares, subject to redemption rights at approximately $10.05 per share, and the sponsor holding Class B founder shares. Institutional shareholders disclosed in the filing include Wolverine Asset Management LLC (9.9%), LMR Partners LLP (8.6%), Magnetar Financial LLC (8.5%), The Goldman Sachs Group Inc. (6.9%), First Trust Capital Management L.P. (6.4%), Barclays PLC (6.3%), AQR Capital Management LLC (5.6%), and First Trust Merger Arbitrage Fund (5.6%), all as of their respective Schedule 13G/13G-A filing dates in 2025.

Value-chain role

VACH functions as a blank-check acquisition vehicle. Its role in the value chain is to raise public capital, hold it in trust, and deploy it into a single business combination. Post-combination, the SPAC entity ceases to exist as an independent public company.

Geographic exposure

VACH is incorporated and operates as a Cayman Islands-based entity listed on the Nasdaq Global Market. The filing was made with the SEC in Washington, D.C. No commercial geographic operations are disclosed.

Source: SEC 10-K, filed 2026-03-10

Industry: Biological Products, (No Diagnostic Substances)